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History of intervention for acute 
ischaemic stroke
In 1995, the National Institute of Neurological Disorders and Stroke 
(NINDS) demonstrated that treatment with intravenous recombinant 
tissue plasminogen activator (IV r-tPA) within 3 hours of onset of 
ischaemic stroke improved clinical outcome at 3 months.[1] However, 
there was less benefit to patients with proximal or large-vessel 
occlusion, possibly because the clot burden and nature of the lesion 
meant that thrombolysis was less effective than in smaller-vessel 
occlusions. In 1998, ECASS (European Cooperative Acute Stroke 
Study) extended the benefit of IV r-tPA to 4.5 hours.[2] In 1999, 
the PROACT II (Prolyse in Acute Cerebral Thromboembolism II) 
trial demonstrated the efficacy of intra-arterial pro-urokinase for 
proven middle cerebral artery occlusion.[3] These early endovascular 
approaches ultimately led to the development of mechanical 
thrombectomy. 
The first mechanical intra-arterial clot-retrieval endovascular 
device, the MERCI Retriever (UCLA, USA), used in the MERCI 
(Mechanical Embolus Removal in Cerebral Ischemia) trial in 2005, 
showed a recanalisation rate of 46% by the MERCI device alone 
and 60.8% when combined with IV r-tPA.[4] However, intracranial 
haemorrhage occurred in 7.8% of patients. In the Multi MERCI trial a 
later-generation MERCI device was used, which demonstrated a 69.5% 
recanalisation rate with favourable clinical outcomes in 34%; however, 
the trial did not include a control therapy group.[5] Optimism about 
mechanical thrombectomy diminished when 3 early randomised 
controlled trials (RCTs) published in 2013 (IMS III (Interventional 
Management of Stroke III), MR RESCUE (Mechanical Retrieval and 
Recanalization of Stroke Clots Using Embolectomy) and SYNTHESIS 
(Local Versus Systemic Thrombolysis for Acute Ischemic Stroke)) 
failed to show improved efficacy of endovascular clot retrieval 
compared with IV r-tPA alone.[6] Limitations of these early trials were 
as follows: patient selection (proven large-vessel occlusion was not 
a requirement for inclusion), use of older technology (mainly first-
generation clot retrieval devices) and a long delay from stroke onset 
to intervention. However, a post hoc subgroup analysis still showed 
benefit in patients with proven large-vessel occlusion who underwent 
endovascular clot retrieval within 90 minutes of IV r-tPA.[7]
Current evidence for mechanical 
thrombectomy
A paradigm shift occurred in 2015 with the publication, in rapid 
succession, of 5 landmark RCTs that tested new-generation stent 
retriever devices. These trials showed consistent superiority of 
endovascular clot retrieval over standard medical therapy in reducing 
disability at 90 days, as measured by the modified Rankin scale (mRS) 
(Table 1) in patients with acute ischaemic stroke (AIS) due to large-
vessel occlusion in the anterior circulation.[8] 
The first study was MR CLEAN (Multicenter Randomised Clinical 
Trial of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands), with all subsequent studies discontinued early owing 
to efficacy, loss of equipoise or both. Functional independence 
(mRS 0 - 2) was achieved in up to 60% of patients. There was an 
absolute benefit of 13.5 - 31% for patients who had undergone 
mechanical thrombectomy compared with those who received best 
medical treatment alone. Some key features of these trials are 
summarised in Table 2. In contrast to the earlier RCTs, selection was 
confined to patients with proven large-vessel occlusion diagnosed 
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Table 1. Modified Rankin scale 
Score Description   
0 No symptoms at all
1 No significant disability despite symptoms; able to carry out all usual duties and activities
2 Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
3 Moderate disability; requires some help, but able to walk without assistance
4 Moderately severe disability; unable to walk without assistance and unable to attend to bodily needs without assistance
5 Severe disability; bedridden, incontinent and requires constant nursing care and attention
6 Dead
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on computed tomography (CT) angiography, randomisation of 
patients within 6 hours of stroke onset and mandatory use of newer-
generation stent retrievers in the later trials. 
HERMES (Highly Effective Reperfusion Evaluated in Multiple 
Endovascular Stroke) trials pooled data from the abovementioned 
5 trials in a meta-analysis to investigate outcomes in subgroups 
that were too small to investigate in the individual trials.[9] A total 
of 1 287 patients (n=634 endovascular therapy patients and n=653 
controls) were included. There was significantly reduced disability 
at 90 days in the endovascular group, with good (independent) 
functional outcome (mRS 0 - 2) in 46% compared with 26.5% in 
the medical control group. Subgroup analysis further showed that 
benefit was seen in patients >80 years of age, those randomised 
>300 minutes after onset and those not eligible for IV r-tPA. There 
was no difference in risk of symptomatic intracerebral haemorrhage 
at 90 days. The number needed to treat for patients to achieve an 
improvement of ≥1 points on mRS was 2.6. This provided robust 
evidence for the safety and efficacy of mechanical thrombectomy 
for most patients with AIS caused by occlusion of proximal anterior 
circulation, irrespective of patient characteristics or geographical 
location. Subsequent RCTs (THRACE (mechanical thrombectomy 
after intravenous alteplase versus alteplase alone after stroke), 
THERAPY (The Randomized, Concurrent Controlled Trial to Assess 
the Penumbra System’s Safety and Effectiveness in the Treatment of 
Acute Stroke), PISTE (Pragmatic Ischaemic Stroke Thrombectomy 
Evaluation) and EASI (Endovascular Acute Stroke Intervention)) 
confirmed the benefit of mechanical thrombectomy. Based on 
evidence from these trials, updated practice guidelines were rapidly 
published in the USA, Canada, Europe and the UK, recommending 
that mechanical thrombectomy be provided to patients with occlusion 
of the internal carotid artery or proximal middle cerebral artery who 
had received treatment with IV r-tPA within 4.5 hours of onset and 
who could undergo the procedure (arterial puncture) within 6 hours 
of symptom onset.[7]
Patient selection
The decision for mechanical thrombectomy should be made by 
a physician trained in the diagnosis and treatment of stroke, in 
conjunction with a neurointerventionalist who has the relevant 
images (non-contrast CT of the brain and a CT angiogram) available 
for review. Prompt assessment of stroke severity using the National 
Institute of Health Stroke Score (NIHSS (Table 3)), baseline functional 
status (mRS) and consideration of comorbidities is essential. To 
achieve optimal clinical outcomes, patient selection criteria should 
parallel those of the successful mechanical thrombectomy trials:
• Documented anterior circulation large-vessel occlusion (proximal 
middle cerebral artery, anterior cerebral or internal carotid artery).
• Significant clinical deficit at the time of assessment (NIHSS >5).
• Lack of extensive early ischaemic change (ASPECTS (Alberta 
Stroke Program Early CT Score) >5) as assessed on non-contrast 
CT of the brain. ASPECTS is a 10-point quantitative score (Fig. 1). Each 
area of the middle cerebral artery territory is allocated 1 point. 
For each region showing ischaemic change, 1 point is deducted. 
A normal CT scan receives an ASPECT score of 10 points; a 
score of <7 is equal to involvement of one-third of the middle 
cerebral artery territory. A score of 0 indicates diffuse ischaemic 
involvement throughout the middle cerebral artery territory. 
• Reasonable pre-stroke functional status and lack of serious 
comorbidities, indicating potential to benefit from treatment 
(age >80 years alone is not a contraindication for treatment). 
• Treatment with IV r-tPA within 4.5 hours (patients ineligible for 
IV r-tPA owing to bleeding risk can be considered for treatment).
• The occluded vessel can be opened by mechanical thrombectomy 
within 6 hours.
The speed of delivery of mechanical thrombectomy is key to 
achieving the best possible outcomes. Therefore, the question of 
benefit in patients with unwitnessed stroke, wake-up stroke (a 
patient goes to bed well, but wakes up with symptoms of a stroke) 
or delayed presentation after 6 - 8 hours, requires assessment with 
more advanced imaging. The DAWN trial (Diffusion Weighted 
Imaging (DWI) or Computerized Tomography Perfusion (CTP) 
Assessment with Clinical Mismatch in the Triage of Wake Up 
and Late Presenting Strokes Undergoing Neurointervention) was a 
prospective, multicentre RCT comparing mechanical thrombectomy 
Table 2. Summary of randomised controlled acute stroke trials
MR CLEAN ESCAPE EXTEND-IA SWIFT PRIME REVASCAT
Time to EVT, hours <6 <12 <6 <6 <8 
ASPECTS 9 9 Perfusion imaging 9 7 - 8
IV r-tPA used, % 87 73 100 100 68
Time to groin, min 260 241 210 224 269
Use of stent retriever, % 81 86 100 100 100
mRS 0 - 2 at 90 days, % 32.6 53 71.4 60 -
Absolute improvement, % 13.5 23.7 31.4 24.7 15.5
TICI 2b/3 reperfusion, % 58 72 86 88 65
EVT Intra-arterial Intra-arterial Solitaire Solitaire Solitaire
NIHSS, median 17 16 17 17 17
Symptomatic ICH, % 7.7/6.4 3.6/2.7 0/5.7 0/3.1 1.9/1.9
MR CLEAN = Multicenter Randomised Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; ESCAPE = Endovascular Treatment for Small Core and 
Proximal Occlusion Ischemic Stroke; EXTEND-IA = Extending the Time for Thrombolysis in Emergency Neurological Deficits – Intra-Arterial; SWIFT PRIME = Solitaire with the Intention 
for Thrombectomy as PRIMary Endovascular Treatment; REVASCAT = Thrombectomy within 8 hours of symptom onset in ischemic stroke; EVT = endovascular therapy; ASPECTS = Alberta 
Stroke Program Early CT Score; IV r-tPA = intravenous recombinant tissue plasminogen activator; mRS = modified Rankin scale; TICI = thrombolysis in cerebral infarction; NIHSS = National 
Institute of Health Stroke Score; ICH = intracerebral haemorrhage.
Table 3. National Institute of Health Stroke Score (NIHSS)*
Score Stroke severity
0 No stroke symptoms
1 - 4 Minor stroke
5 - 15 Moderate stroke
16 - 20 Moderate to severe stroke
21 - 42 Severe stroke
*Parameters scored: level of consciousness, horizontal eye movements, visual fields, 
facial palsy, motor function – arms, motor function – leg, limb ataxia, sensory, language, 
speech, extinction/inattention.
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and medical treatment with medical treat-
ment alone for AIS. The therapeutic window 
was extended to 24 hours. Patients had to 
have proven large-vessel occlusion and an 
NIHSS ≥10. Advanced imaging (DWI or CT 
perfusion) was used to assess core infarct 
volume relative to volume of salvageable 
penum bra. A total of 206 patients were enroll -
ed (enrolment discontinued before the target 
of 500 after interim analysis). Results showed 
significantly reduced post-stroke disability 
and improved functional independence at 
90 days (48.6% v. 13.1%) in the endovascular 
group. There was a relative reduction in 
disability of 73%, with 1 in 2.8 patients saved 
from severe disability.[10] The DEFUSE-3 
trial (Endovascular Therapy Following 
Imaging Evaluation for Ischemic Stroke) also 
showed improved functional outcomes with 
mechanical thrombectomy for ischaemic 
stroke 6 - 16 hours after onset compared 
with medical therapy alone for patients with 
anterior circulation large-vessel occlusion 
and a region of tissue that was ischaemic but 
not yet infarcted.[11] 
Practical aspects 
Devices and techniques
After successful RCTs, the Solitaire FR 
(Medtronic, USA) stent retriever became the 
benchmark for mechanical thrombectomy. 
However, rapid and safe recanalisation and 
reperfusion of the occluded territory is the 
key factor, rather than any specific device 
or technique. Multiple options are available, 
including the use of supplementary devices, 
such as balloon-guide catheters, intermediate 
catheters and suction pumps v. manual 
aspiration.[7] After femoral artery puncture, 
an 8 Fr guide catheter is navigated into the 
internal carotid artery, where an intermediate 
catheter (5 - 6 Fr) is directed to the circle 
of Willis. Through this, a microcatheter is 
navigated under fluoroscopic guidance distal 
to the clot over a microwire. The microwire 
is removed and a run is done through the 
microcatheter to confirm position past the 
clot, filling the distal occluded territory. 
The stent retriever is navigated through the 
microcatheter, positioned at the level of the 
clot and opened by unsheathing, i.e. pulling 
the microcatheter back while keeping the 
stent in place. This exposes the struts of the 
stent to the clot. Once the stent is integrated 
into the clot, the device is pulled back into 
the intermediate catheter, which has suction 
applied simultaneously. A balloon guide, 
forming a cuff around the guide catheter, 
may be used to stop the forward flow and 
reduce the chance of distal emboli. When 
using such a guide, the intermediate catheter 
may be omitted. Fig. 2 shows angiographic 
images of mechanical thrombectomy in a 
59-year-old man who presented with acute 
right hemiparesis and dysphasia. The freshly 
removed clot in the stent retriever device 
is shown in Fig. 3. The patient’s functional 
status improved to mRS 1 after mechanical 
thrombectomy. 
An increasingly popular approach is to 
attempt to aspirate the clot directly into the 
intermediate catheter, which has become 
feasible since the advent of large-lumen soft 
catheters that can be safely navigated into the 
M1 segment of the middle cerebral artery 
and beyond. It is critical to choose a catheter 
with a lumen approaching the size of the 
vessel where the clot is lodged, allowing 
the clot to be suctioned completely. If this 
fails, a stent retriever may be easily deployed 
through the initial system. 
Anaesthesia
The use of general anaesthesia (GA) v. local 
anaesthesia (conscious sedation) currently 
varies, with each strategy having potential 
advantages. GA associated with systolic 
blood pressure <140 mmHg was also 
associated with poor functional outcome 
(mRS >2) at 90 days. However, more recent 
studies suggest that GA and conscious 
sedation are equally safe; therefore, the 
choice should be individualised, based on 
patient and institutional factors.[12,13] 
Complications 
The complications of endovascular proce-
dures can be device related, access related 
or contrast related. Device-related complica-
tions include vessel perforation, symptom-
atic intracranial haemorrhage, subarachnoid 
haemorrhage, arterial dissection, emboli 
to new vascular territories and vasospasm. 
Access-related complications include femoral 
artery dissection, pseudoaneurysm, retro-
peritoneal haematoma and infection. The 
overall procedural complication rate from 
recent RCTs is ~15%; however, many of these 
complications do not adversely affect clinical 
outcome. 
Who should perform mechanical 
thrombectomy?
To minimise complications, the key strat-
egy is for mechanical thrombectomy to be 
performed only in high-volume centres 
by trained physicians competent in intra-
cranial endovascular procedures and who 
undertake these regularly to maintain skills. 
Mechanical thrombectomy should only be 
performed in the context of a multidiscipli-
nary team, operating in comprehensive stroke 
Fig. 2. Digital subtraction angiogram during mechanical thrombectomy. (A) Left internal carotid artery 
injection showing proximal middle cerebral artery (MCA) occlusion (arrow). (B) Contrast injection 
from microcatheter distal to thrombus. (C) Reperfusion of the previously occluded MCA territory after 
thrombectomy.
Fig. 1. ASPECTS (Alberta Stroke Program Early CT Score). A = at level of basal ganglia; B = at level 
of ventricles immediately above basal ganglia; CT = computed tomography; CN = caudate nucleus; 
IC = internal capsule; LN = lentiform nucleus; I = insular cortex; M1 = anterior middle cerebral artery 
(MCA) cortex; M2 = lateral MCA cortex; M3 = posterior MCA cortex; M4 = anterior MCA cortex 
superior to M1; M5 = lateral MCA cortex superior to M2; M6 = posterior MCA cortex superior to M3; 
A (yellow) = anterior; P (yellow) = posterior.
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centres with adequate neurointerventional procedural volumes (e.g. 
>200 per year), of which a reasonable proportion are mechanical 
thrombectomy, and where regular assessment/audit of technical and 
clinical results, process times and complications is undertaken.[7] 
When complications do occur, the immediate availability of neuro-
critical care and/or neurosurgical support is mandatory and may be 
lifesaving. 
Challenges and future questions
The practical implementation of mechanical thrombectomy in 
South Africa (SA) presents many challenges. For the trial results to 
be replicated, identification and support of comprehensive stroke 
units with appropriate referral pathways of selected patients from 
primary stroke centres are needed.[14] A comprehensive stroke 
unit should include qualified neurointerventionalists who are 
able to offer mechanical thrombectomy 24 hours a day, 7 days a 
week. To get the right patient to the right place within the right 
time frame requires reorganisation of SA stroke services that 
involves substantial investment, great attention to care pathways 
and extensive co-operation between services, including ambulances 
and hospitals. 
The value of mechanical thrombectomy for posterior circulation 
strokes, distal middle cerebral artery strokes, mild stroke symptoms 
(NIHSS <5) and the role of direct thrombectomy without IV r-tPA 
remain to be defined. Ongoing RCTs should provide these answers 
in the next 3 - 5 years. 
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Fig. 3. Freshly removed clot in stent retriever device.
